HUP0104756A2 - Poliol/olaj szuszpenziók a fehérjék folyamatos kibocsátásához - Google Patents

Poliol/olaj szuszpenziók a fehérjék folyamatos kibocsátásához

Info

Publication number
HUP0104756A2
HUP0104756A2 HU0104756A HUP0104756A HUP0104756A2 HU P0104756 A2 HUP0104756 A2 HU P0104756A2 HU 0104756 A HU0104756 A HU 0104756A HU P0104756 A HUP0104756 A HU P0104756A HU P0104756 A2 HUP0104756 A2 HU P0104756A2
Authority
HU
Hungary
Prior art keywords
polyol
proteins
oil suspensions
sustained release
active agent
Prior art date
Application number
HU0104756A
Other languages
English (en)
Inventor
Alice C. Beekman
Merrill Seymour Goldenberg
Daxian Shan
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/221,181 external-priority patent/US6245740B1/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of HUP0104756A2 publication Critical patent/HUP0104756A2/hu
Publication of HUP0104756A3 publication Critical patent/HUP0104756A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)

Abstract

A tal lm ny poliol/vastagított olaj szuszpenzió készítményekrevonatkozik, melyek a biológiailag aktív szer folyamatos sz llít s hozbiológiailag aktív szert tartalmaznak. A leírt fehérje/glicerin/olajszuszpenziók a fehérjék, mint péld ul a G-CSF folyamatos kibocs t s raképesek, legal bb egy hétig. Ó
HU0104756A 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins HUP0104756A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/221,181 US6245740B1 (en) 1998-12-23 1998-12-23 Polyol:oil suspensions for the sustained release of proteins
US44820599A 1999-11-23 1999-11-23
PCT/US1999/030527 WO2000038652A1 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Publications (2)

Publication Number Publication Date
HUP0104756A2 true HUP0104756A2 (hu) 2002-04-29
HUP0104756A3 HUP0104756A3 (en) 2006-04-28

Family

ID=26915566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104756A HUP0104756A3 (en) 1998-12-23 1999-12-20 Polyol/oil suspensions for the sustained release of proteins

Country Status (16)

Country Link
EP (1) EP1140018B1 (hu)
JP (1) JP2002533378A (hu)
KR (1) KR100491815B1 (hu)
CN (1) CN1158068C (hu)
AT (1) ATE251448T1 (hu)
AU (1) AU769610B2 (hu)
CA (1) CA2355618C (hu)
DE (1) DE69911993T2 (hu)
DK (1) DK1140018T3 (hu)
ES (1) ES2204187T3 (hu)
HU (1) HUP0104756A3 (hu)
IL (2) IL143706A0 (hu)
PT (1) PT1140018E (hu)
SI (1) SI1140018T1 (hu)
TW (1) TWI221777B (hu)
WO (1) WO2000038652A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DK1274459T3 (da) 2000-04-19 2006-02-06 Genentech Inc Præparater med vedholdende frigivelse indeholdende væksthormon
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
WO2003000282A1 (en) * 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
CA2667678A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
KR101434706B1 (ko) * 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 미립자 유성 현탁액을 포함하는 의약 조성물
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61500439A (ja) * 1983-11-21 1986-03-13 リ−ジエンツ　オヴ　ザ　ユニヴア−シテイ−　オヴ　ミネソタ 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
US5114929A (en) * 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions

Also Published As

Publication number Publication date
ES2204187T3 (es) 2004-04-16
JP2002533378A (ja) 2002-10-08
CN1158068C (zh) 2004-07-21
KR100491815B1 (ko) 2005-05-27
HUP0104756A3 (en) 2006-04-28
IL143706A (en) 2008-04-13
ATE251448T1 (de) 2003-10-15
EP1140018A1 (en) 2001-10-10
CN1335765A (zh) 2002-02-13
DE69911993D1 (de) 2003-11-13
KR20010099864A (ko) 2001-11-09
PT1140018E (pt) 2004-02-27
AU2483800A (en) 2000-07-31
CA2355618C (en) 2007-03-13
EP1140018B1 (en) 2003-10-08
IL143706A0 (en) 2002-04-21
TWI221777B (en) 2004-10-11
DE69911993T2 (de) 2004-05-19
AU769610B2 (en) 2004-01-29
SI1140018T1 (en) 2003-12-31
WO2000038652A1 (en) 2000-07-06
CA2355618A1 (en) 2000-07-06
DK1140018T3 (da) 2004-02-02

Similar Documents

Publication Publication Date Title
HUP0104756A2 (hu) Poliol/olaj szuszpenziók a fehérjék folyamatos kibocsátásához
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
JP2001506668A5 (hu)
AU1593001A (en) Recombinant gelatin in vaccines
AU2001220765A1 (en) Mixed buffer system for stabilizing polypeptide formulations
WO2001022936A8 (en) Topical suspension formulations containing ciprofloxacin and dexamethasone
AU1213901A (en) Emulsion compositions for polyfunctional active ingredients
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
FI970825A (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
BR0215405A (pt) Composições e processos de uso de collajolie
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69732309D1 (de) Primerzusammensetzungen für den Dentalbereich
DE60007584D1 (de) Aktives, hydraulisches, schwingungsdämpfendes Lager und dieses Lager enthaltendes System
NO993453D0 (no) Vannbasert suspensjon til nasal administrering
ZA991181B (en) Thickened emulsion compositions for use as propellants and explosives.
BR0210493A (pt) Composição, e, método para remover cerume humano
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
FI963716A (fi) Glykolyyttisen reitin entsyymejä koodittava, alkoholia tuottavissa hiivoissa käytettävä DNA
UY27373A1 (es) Formulaciones de interferón beta-humano
EP0995430A3 (de) Verwendung von Wirkstoffen, gewählt aus der Gruppe der 1,2-Diacylglycerole, zur Stärkung der Barrierefunktion der Haut
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE28188T1 (de) Antikonvulsive mittel.
ATE305517T1 (de) Neurotrypsin
WO2001037780A8 (en) Urotensin-ii analogs

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees